Proellex

Repros' Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids

THE WOODLANDS, Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced final results of a U.S. Phase 2 study of Proellex(TM), an oral drug being developed to relieve symptoms of uterine fibroids. This study suggests that treatment with Proellex results in a statisti...

Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 11, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today released top-line findings from its six month study of Proellex in the treatment of endometriosis. This study, conducted in Europe, enrolled 39 premenopausal women and has completed six months of do...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) today announced that an article has been published in the July 1, 2007 issue of Oncology Reports indicating a potential for a new approach to the treatment of breast cancer using Proellex. The article revi...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

...ine fibroids, a condition that affects numerous women of childbearing age in the U.S. and results in a significant number of hysterectomies each year. proellex is also being studied in a six month European Phase 1/2 study for the treatment of endometriosis, a condition that affects approximately 5.5 million w...